ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1165

Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review

Sohail Farshad1, Alexandra Halalau 2, Whitney Townsend 3 and Elena Schiopu 4, 1Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, 2Department of Internal Medicine, Beaumont Health System, Royal Oak, 3University of Michigan, Ann Arbor, 4Department of Rheumatology, University of Michigan, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: connective tissue diseases and computed tomography (CT), coronary artery disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Imaging Of Rheumatic Diseases Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent literature shows that connective tissue disorders (CTDs) are positively associated with subclinical atherosclerosis via chronic activation of inflammatory pathways, or direct endothelial injury. Multidetector computed tomography (MDCT) is non-invasive and has emerged as a modality of estimating coronary calcium score (CCS) and prevalence of coronary arterial calcium (CAC) as a potential marker of risk for cardiac events, such as myocardial infarction. The objective of our study is to assess the utility of CCS, based on the current published data in CTDs as it relates to the presence of coronary atherosclerosis in CTDs.

Methods: Following the PRIMSA guidelines, a literature search was done in PubMed, Embase, Scopus, Web of Science Core Collection, CINAHL, and Cochrane Database of Systematic Review. Inclusion criteria consisted of studies that investigated CCS in adults across the spectrum of CTDs, such as: rheumatoid arthritis (RA), seronegative spondyloarthropathies, systemic lupus erythematous (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM) and vasculitides. Studies were excluded if a complete manuscript was not written in English, or if it was a single case report. The quality of articles included were assessed using the Newcastle-Ottawa Scale (NOS) assessment scale for cohort studies and the Agency for Healthcare Research and Quality (AHRQ) criteria for cross-sectional studies.

Results: The initial search revealed 1907 citations, but after we eliminated duplicates, studies that did not reference CCS/CAC, and abstracts only, we reviewed 121 full text publications (Figure 1). 31 studies were included in this review (27 with healthy age/gender matched control group and 4 without). The CTDs analyzed in articles with a control group for comparison (Table 1) were: 11 RA, 14 SLE, 4 SSc, 1 IIM, 1 Takayasu arteritis, and 1 psoriasis. 9 out of 11 RA studies, 12 out of 14 SLE studies, and 2 out of 4 SSc studies showed statistically significant increased CCS or CAC prevalence/incidence when compared to control group. The CTDs analyzed without a control group for comparison (Table 2) were: 2 Kawasaki disease, 1 juvenile idiopathic arthritis (JIA), and 1 antiphospholipid syndrome (APS). These studies demonstrated increased CAC burden, however without statistically significant data.

Conclusion: This systematic review demonstrates that some CTDs (RA and SLE) have higher CCS and/or CAC incidence/prevalence compared to normal controls, while the SSc data is still ambiguous. This study also identified that aside from Takayasu arteritis and Kawasaki disease, there is currently no published data in the spectrum of vasculitides, which are associated with high inflammatory burden. Based on the current published data, it is unclear if MDCT-measured CCS is a reliable and generalizable tool to assess subclinical atherosclerosis across the spectrum of CTDs, however we ascertain that it can be useful for cardiovascular risk assessment in patients with SLE and RA.


Figure 1 Flow Diagram

Figure 1. Flow Diagram – Search design


Table 1 – Final

Table 1. Descriptive summary of CCS/CAC of CTDs with control group for comparison.


Table 2 – Final

Table 2. Descriptive summary of CCS/CAC of CTDs without control group for comparison.


Disclosure: S. Farshad, None; A. Halalau, None; W. Townsend, None; E. Schiopu, None.

To cite this abstract in AMA style:

Farshad S, Halalau A, Townsend W, Schiopu E. Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/utility-of-coronary-calcium-scoring-ccs-in-the-spectrum-of-connective-tissue-disorders-ctds-for-the-evaluation-of-subclinical-coronary-atherosclerosis-a-systematic-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-coronary-calcium-scoring-ccs-in-the-spectrum-of-connective-tissue-disorders-ctds-for-the-evaluation-of-subclinical-coronary-atherosclerosis-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology